Sergey V. Karakashev
Affiliations: | 2011-2015 | Biochemistry | Drexel University College of Medicine, Philadelphia, PA, United States |
Google:
"Sergey Karakashev"Parents
Sign in to add mentor| Mauricio J. Reginato | grad student | 2011-2015 | Drexel Medical School | |
| (Role of hypoxia in mediating resistance to breast cancer therapy) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kumari S, Gupta S, Jamil A, et al. (2024) Exploring Metabolic Approaches for Epithelial Ovarian Cancer Therapy. Journal of Cellular Physiology. e31495 |
| Liu H, Lin J, Zhou W, et al. (2022) KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. Cancer Immunology Research. OF1-OF11 |
| Lin J, Liu H, Fukumoto T, et al. (2021) Targeting the IRE1α/XBP1s pathway suppresses CARM1-expressing ovarian cancer. Nature Communications. 12: 5321 |
| Wu S, Fukumoto T, Lin J, et al. (2021) Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nature Cancer. 2: 189-200 |
| Karakashev S, Zhang R. (2020) Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors. Molecular & Cellular Oncology. 7: 1760675 |
| Fukumoto T, Fatkhutdinov N, Zundell JA, et al. (2019) HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer. Cancer Research |
| Fukumoto T, Zhu H, Nacarelli T, et al. (2019) N6-methylation of adenosine (m6A) of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Research |
| Fukumoto T, Park PH, Wu S, et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Reports. 22: 3393-3400 |
| Karakashev S, Zhu H, Wu S, et al. (2018) CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nature Communications. 9: 631 |
| Karakashev S, Zhu H, Yokoyama Y, et al. (2017) BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Reports. 21: 3398-3405 |